Belgian Pharma Co to Pay $34M for Off-Label Drug Promotion
The Justice Department has announced that the U.S. subsidiary of Belgian pharmaceutical manufacturer UCB SA has pleaded guilty to the off-label promotion of its epilepsy drug Keppra for use in the treatment of migraines, in violation of the Food, Drug…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
and Cosmetic (FD&C) Act. UCB will pay more than $34 million to resolve criminal and civil liability arising out of its illegal conduct.